Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors are antihyperglycemic drugs that inhibit glucose reabsorption in the proximal tubule via SGLT2, resulting in glucosuria, which in turn reduces hyperglycemia (9). This evidence concerns the gene SLC5A2 and Hyperglycemia.